Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXT-1003 and Enzalutamide in mCRPC
NCT07897071Phase 1Recruiting
- Sponsor
- Axter Therapeutics
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of AXT-1003 in prostate cancer (PCa) (2 arms), sponsored by Axter Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events and Serious Adverse Events at 3 years. Started Sep 2026; status: recruiting.
02
Drugs
AXT-1003
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07897071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897071.